These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31899485)

  • 1. Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease.
    Seemann S; Ernst M; Cimmaruta C; Struckmann S; Cozma C; Koczan D; Knospe AM; Haake LR; Citro V; Bräuer AU; Andreotti G; Cubellis MV; Fuellen G; Hermann A; Giese AK; Rolfs A; Lukas J
    Biochem J; 2020 Jan; 477(2):359-380. PubMed ID: 31899485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
    Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
    ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological chaperone therapy for Fabry disease.
    Ishii S
    Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
    Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
    Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme enhancers for the treatment of Fabry and Pompe disease.
    Lukas J; Pockrandt AM; Seemann S; Sharif M; Runge F; Pohlers S; Zheng C; Gläser A; Beller M; Rolfs A; Giese AK
    Mol Ther; 2015 Mar; 23(3):456-64. PubMed ID: 25409744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat.
    Braunstein H; Papazian M; Maor G; Lukas J; Rolfs A; Horowitz M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chaperone Therapy in Fabry Disease.
    Weidemann F; Jovanovic A; Herrmann K; Vardarli I
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
    Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
    J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.
    Citro V; Cammisa M; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
    Yam GH; Roth J; Zuber C
    Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ; Ishii S; Asano N; Suzuki Y
    Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
    Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.